Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2U3MX)

Drug Name

VX-509 Drug Info

Synonyms

Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2/3	[1]

Cross-matching ID

PubChem CID: 59422203
CAS Number: CAS 944842-54-0
TTD Drug ID: DM2U3MX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[3]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[4]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[5]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[4]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[6]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[7]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[8]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[4]
GDC-0214	DMCNSII	Asthma	CA23	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8309).
2	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
6	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
7	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
9	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
10	Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789.